Tanezumab In Osteoarthritis Of The Knee (2)

Pfizer

Status and phase: Completed; Phase 3

Conditions: Osteoarthritis; Arthritis

Treatments: Drug: naproxen; Biological: tanezumab 5 mg; Biological: tanezumab 10 mg; Other: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00830063

A4091015

P3 OA KNEE NSAID POPULATION (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.

Enrollment: 832 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Osteoarthritis of the knee according to Kellgren-Lawrence x-ray grade of 2

Exclusion criteria

• Pregnancy or intent to become pregnant
• BMI greater than 39
• other severe pain, significant cardiac, neurologic or cardiac disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

832 participants in 4 patient groups, including a placebo group

1

Experimental group

Treatment:

Biological: tanezumab 10 mg

2

Experimental group

Treatment:

Biological: tanezumab 5 mg

3

Active Comparator group

Treatment:

Drug: naproxen

4

Placebo Comparator group

Treatment:

Other: placebo